Pfizer reveals pitfalls leading to prosecution in the pharma industry

April 18, 2012 - PRLog -- Pharma IQ: In this new heightened risk management environment, what are you seeing as the most common concerns of pharma companies when it comes to compliance regulatory investigations?

J Holzer: Like in past years, potential corruption involving government officials as well as promotion and marketing activities really are popular areas of concern for pharma companies and companies worldwide in general. With the global nature of commerce though and increased compliance in global trade areas companies are increasingly looking at their level of compliance with global trade laws, and that’s import laws and export laws and certainly the sanctions and embargoes area with all of the changes after last year’s involvement of all the Middle East and Northern African countries in changes in political structure and restricted parties. And they’re putting resources towards dealing with those areas and they’re particularly important because they’re really complex and in-depth and the laws do change from country to country and they should be harmonised but they’re not necessarily that way.

To download this interview in full, please click here - http://www.pharmaediscovery.com/Event.aspx?id=722482&utm_... &utm_medium=HWOnline&utm_source=Linked In&MAC=HW_PROMO_21245.001  _LI